Hepatitis C Virus is a quickly evolving area within hepatology owing to new medical therapies. This issue, guest edited by Dr. Fred Poordad, includes the most current clinical information and treatment therapies. Expert authors have written review articles devoted to the following medical therapies: Boceprevir, Telaprevir, Protease Inhibitors in Development, NS5B Nucleoside and Non-Nucleoside Inhibitors. Review articles also address important patients like na�ve- and non-responders and relapsers, the HIV co-infected patient, and the Genotype 1 and non-Genotype 1 patient.
